Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics Inc (CTMX) is a clinical-stage biopharmaceutical pioneer developing conditionally activated cancer therapies through its probody technology platform. This dedicated news hub provides investors and researchers with essential updates on clinical advancements, strategic collaborations, and therapeutic innovations in oncology.
Access real-time updates on CTMX's probody-based candidates, including antibody drug conjugates and T-cell engagers. The platform centralizes critical developments such as trial milestones, partnership expansions with industry leaders like Astellas and Merck, and financial disclosures - all vital for informed analysis of this innovative oncology company.
Key content categories include clinical program progress, regulatory updates, scientific presentations, and corporate financial results. Each update is curated to highlight how CTMX's tumor-activated therapies aim to improve cancer treatment safety profiles while maintaining therapeutic efficacy.
Bookmark this page for streamlined access to verified CTMX developments. Regularly updated with official press releases and objective reporting, it serves as your primary resource for tracking advancements in conditionally activated cancer immunotherapies.
CytomX Therapeutics (NASDAQ:CTMX) announces the retirement of W. Michael Kavanaugh, M.D., its Chief Scientific Officer, effective December 1, 2020. He will continue as an advisor on the Scientific Advisory Board. Marcia P. Belvin, Ph.D., is promoted to Senior Vice President, Head of Research, bringing nearly 20 years of oncology experience. CytomX focuses on developing Probody therapeutics, which selectively target tumors while minimizing toxicity to healthy tissues. The company's pipeline includes innovative candidates like CX-2009 and CX-2029, aimed at previously undruggable cancer targets.
CytomX Therapeutics (NASDAQ: CTMX) announced the granting of stock options to nine new employees on September 15, 2020. A total of 211,000 shares were issued at an exercise price of $7.22, equal to the closing price on that date. This action is part of the Company's 2019 Employment Inducement Incentive Plan, aimed at attracting talent. CytomX is a clinical-stage biopharmaceutical company focused on oncology, utilizing its Probody technology to develop innovative cancer treatments, partnering with major industry players like AbbVie and Bristol Myers Squibb.
CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in two virtual healthcare conferences in September 2020. The events are the Citi’s 15th Annual BioPharma Virtual Conference on September 10, 2020, and the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 12:00 p.m. ET. A live audio webcast of the latter will be available on CytomX's website, with a 90-day archive. CytomX is pioneering a novel class of antibody therapeutics for cancer treatment, collaborating with major biotech firms to develop innovative therapies.
CytomX Therapeutics (CTMX) announced its second-quarter 2020 financial results, reporting revenue of $16.6 million, up from $9.0 million in Q2 2019. The increase is attributed to revenue from collaborations, including an $80 million upfront payment from Astellas. Cash and equivalents rose to $346.4 million as of June 30, 2020. The company is advancing its clinical pipeline, which includes notable drug candidates like CX-2029 and CX-2009, with plans for Phase 2 cohorts later this year despite COVID-19 challenges. R&D expenses decreased by $6.8 million year-over-year, showcasing effective cost management.
CytomX Therapeutics (Nasdaq: CTMX) announced that Dr. Sean McCarthy, CEO, will present at the 2020 Wedbush PacGrow Virtual Healthcare Conference on August 12, 2020, at 1:10 p.m. ET. The presentation will provide a corporate update and will be available via live audio webcast on the company’s website. CytomX focuses on developing Probody therapeutics designed to selectively target tumors while sparing healthy tissue, aiming to create safer cancer treatments. The company has partnerships with major firms, including AbbVie and Bristol Myers Squibb.
CytomX Therapeutics (CTMX) announced that partner Bristol Myers Squibb presented preclinical data on anti-CTLA-4 Probody therapeutics, BMS-986249 and BMS-986288, at the AACR 2020 Virtual Annual Meeting II. These therapeutics aim to enhance treatment for metastatic melanoma and advanced solid tumors. BMS-986249 is co-administered with Opdivo, while BMS-986288 is under trial for advanced tumors as monotherapy and with nivolumab. Both programs stem from a 2014 collaboration agreement, showcasing the potential of CytomX’s Probody technology in oncology.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) has announced that its CEO, Sean McCarthy, will participate in two virtual healthcare conferences in June 2020. The first event is the Jefferies Virtual Healthcare Conference, where he will present a Corporate Update on June 3 at 11:30 a.m. ET. The second is the Goldman Sachs 41st Annual Global Healthcare Conference on June 10 at 4:40 p.m. ET, where he will engage in a Fireside Chat. Live audio webcasts will be accessible on CytomX's website, with archived replays available for 90 days.
CytomX Therapeutics (CTMX) announced key details regarding oral and poster presentations for its clinical-stage portfolio at the ASCO20 Virtual Scientific Program scheduled from May 29-31, 2020. Presentations for CX-072, CX-2009, and CX-2029 will provide pivotal clinical data, including initial results for CX-2029, a Probody Drug Conjugate targeting CD71. The data cutoff dates for these presentations are five months later than previously set. The company emphasizes the potential of its Probody platform to offer more effective cancer therapies.
CytomX Therapeutics (CTMX) reported its Q1 2020 financial results, highlighting a revenue increase to $49.6 million from $29.5 million in Q1 2019, primarily due to milestone payments from AbbVie and Bristol Myers Squibb. Cash reserves decreased to $247.9 million. The company paused new patient enrollment in its CX-2009 study due to COVID-19 but is focusing on undruggable targets through key collaborations, including an $80 million agreement with Astellas. Despite challenges from the pandemic, CytomX remains poised for future growth with ongoing clinical trials and strategic partnerships.
FAQ
What is the current stock price of Cytomx Therapeutics (CTMX)?
What is the market cap of Cytomx Therapeutics (CTMX)?
